Comparison Chart Monopar Therapeutics Inc.

Stocks

MNPR

US61023L2079

Biotechnology & Medical Research

Delayed Nasdaq 14:16:26 2026-09-11 EDT			5-day change	1st Jan Change
111.17 ^USD	+1.10%		-5.44%	+70.25%

08-19	Monopar Therapeutics Inc. Announces Appointment of Jeffrey D. Kent as Executive Vice President, Head of Medical Affairs, Effective September 1, 2026	CI
08-13	Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	MONOPAR THERAPEUTICS INC.	Other Biotechnology & Medical Research	+1.10%	-5.44%	+70.25%	+133.23%	+332.57%	738M